Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2923-2928

  Lanaspa, Miguel ^a,b   Moraleda, Cinta ^a,b   Machevo, Sónia ^b   González, Raquel ^a,b   Serrano, Beatriz ^a   Macete, Eusebio ^b   Cisteró, Pau ^a   Mayor, Alfredo ^a   Hutchinson, David ^c   Kremsner, Peter G ^d,e   Alonso, Pedro ^a,b   Menéndez, Clara ^a,b   Bassat, Quique ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Ministério de Saúde   (Mozambique)

^c Jomaa Pharma GmbH   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e ALBERT SCHWEITZER HOSPITAL   (Gabon)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; FOSMIDOMYCIN;

ANEMIA; ANOREXIA; AQUEOUS SOLUTION; ARTICLE; BRONCHITIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; INFANT; LEUKOCYTE COUNT; MALARIA; MALARIA FALCIPARUM; MALE; MOZAMBIQUE; OPEN STUDY; PARASITE CLEARANCE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT INFECTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTIMALARIALS; CHILD, PRESCHOOL; CLINDAMYCIN; DRUG THERAPY, COMBINATION; FOSFOMYCIN; HUMANS; INFANT; INFANT, NEWBORN; MALARIA, FALCIPARUM;

EID: 84861120262     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00018-12     Document Type: Article

References (33)

1. Alonso PL, et al. 2004. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364:1411-1420. (Pubitemid 39370716)
2. Alonso PL, et al. 2002. Manhiça DSS, Mozambique, p 189-195. In Population and health in developing countries, 1st ed, vol 1. Population, health, and survival at INDEPTH sites. International Development Research Centre, Ottawa, Canada.
3. Borrmann S, et al. 2004. Fosmidomycin-clindamycin for Plasmodium falciparum infections in African children. J. Infect. Dis. 189:901-908. (Pubitemid 38328192)
4. Borrmann S, et al. 2005. Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 49:3749-3754. (Pubitemid 41233027)
5. Borrmann S, et al. 2004. Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J. Infect. Dis. 190:1534-1540. (Pubitemid 39411000)
6. Borrmann S, et al. 2006. Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 50:2713-2718. (Pubitemid 44198692)
7. Borrmann S, Matsiegui PB, Missinou MA, Kremsner PG. 2008. Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children. Antimicrob. Agents Chemother. 52:1799-1805. (Pubitemid 351614675)
8. Dharia NV, et al. 2010. Genome scanning of Amazonian Plasmodium falciparum shows subtelomeric instability and clindamycin-resistant parasites. Genome Res. 20:1534-1544.
9. Dharia NV, et al. 2009. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol. 10:R21.
10. Djimde AA, et al. 2003. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 69:558-563. (Pubitemid 38248261)
11. Enserink M. 2010. If artemisinin drugs fail, what's plan B? Science 328:846.
12. Greenwood BM, et al. 2008. Malaria: progress, perils, and prospects for eradication. J. Clin. Invest. 118:1266-1276. (Pubitemid 351500419)
13. Kachur SP, MacArthur JR, Slutsker L. 2010. A call to action: addressing the challenge of artemisinin-resistant malaria. Expert Rev. Anti Infect. Ther. 8:365-366.
14. Lell B, Kremsner PG. 2002. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob. Agents Chemother. 46:2315-2320. (Pubitemid 34793429)
15. Lell B, et al. 2003. Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob. Agents Chemother. 47:735-738. (Pubitemid 36158108)
16. malERAConsultative Group on Drugs. 2011. A research agenda for malaria eradication: drugs. PLoS Med. 8:e1000402.
17. Missinou MA, et al. 2002. Fosmidomycin for malaria. Lancet 360:1941-1942. (Pubitemid 35472137)
18. Na-Bangchang K, Ruengweerayut R, Karbwang J, Chauemung A, Hutchinson D. 2007. Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria. Malar. J. 6:70.
19. Noedl H, et al. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
20. Oyakhirome S, et al. 2007. Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 51:1869-1871. (Pubitemid 46744177)
21. Planche T, et al. 2001. Comparison of methods for the rapid laboratory assessment of children with malaria. Am. J. Trop. Med. Hyg. 65:599-602. (Pubitemid 33134599)
22. Puta C, Manyando C. 1997. Enhanced gametocyte production in Fansidar-treated Plasmodium falciparum malaria patients: implications for malaria transmission control programmes. Trop. Med. Int. Health 2:227-229. (Pubitemid 27153325)
23. Ruangweerayut R, et al. 2008. Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria. Malar. J. 7:225.
24. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. 2009. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst. Rev. 3:CD007483.
25. Snounou G, et al. 1999. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans. R. Soc. Trop. Med. Hyg. 93:369-374. (Pubitemid 29405860)
26. Wiesner J, Borrmann S, Jomaa H. 2003. Fosmidomycin for the treatment of malaria. Parasitol. Res. 90(Suppl. 2):S71-S76. (Pubitemid 36831281)
27. Wiesner J, Henschker D, Hutchinson DB, Beck E, Jomaa H. 2002. In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob. Agents Chemother. 46:2889-2894.
28. World Health Organization. 2011. Global plan for artemisinin resistance containment (GPARC). World Health Organization, Geneva, Switzerland.
29. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Orgxanization, Geneva, Switzerland.
30. World Health Organization. 2008. Methods and techniques for clinical trials on antimalarial efficacy: genotyping to identify parasite populations. World Health Organization, Geneva, Switzerland.
31. World Health Organization. 2000. Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. Suppl. 1:1-90.
32. World Health Organization. 2010. The world malaria report. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/publications/atoz/ 9789241564106/en/index.html.
33. Zhang B, et al. 2011. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry 50:3570-3577.